Edelman Joseph's Form 4 filing
Astria Therapeutics, Inc.ATXS · filed Oct 18, 2023
- Accession no.
- 0001062993-23-019533
- Filed
- Oct 18, 2023, 4:11 PM ET
- Trade date
- Oct 16, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 4 derivative transactions. Open-market purchases total $7.00M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Edelman JosephCIK 0001164426 | Director |
| Perceptive Advisors LLCCIK 0001224962 | Director |
| Perceptive Life Sciences Master Fund LtdCIK 0001249675 | Director |
| Perceptive Xontogeny Venture Fund, LPCIK 0001757940 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 16, 2023 | Common Stock | PPurchaseAcquired | +460,546 | $6.51F1 | +$3,999,999.87 | 460,546 | Indirect | |
| Oct 16, 2023 | Common Stock | PPurchaseAcquired | +690,819 | $6.51F2 | +$5,999,078.71 | 1,151,366.25 | Indirect | |
| Oct 16, 2023 | Common Stock | PPurchaseAcquired | +921,093 | $6.51F2 | +$5,999,078.71 | 921,093 | Indirect | |
| Oct 16, 2023 | Common Stock | PPurchaseAcquired | +345,409 | $6.51F1 | +$2,999,996.64 | 345,409 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the combined purchase price for each share of Common Stock and accompanying common warrant purchased by the Reporting Person in the Issuer's registered public offering that closed on October 16, 2023.
Referenced by the price of 2 transactions in Table I and 2 transactions in Table II.
- F2
Represents the combined purchase price for each pre-funded warrant and accompanying common warrant purchased by the Reporting Person in the Issuer's registered public offering that closed on October 16, 2023.
Referenced by the price of 2 transactions in Table II.